- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460352
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (NEEDS)
NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial)
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy. A second co-primary endpoint is global health related quality of life (HRQOL) one year after randomisation. A third co-primary endpoint is eating restictions one year after randomisation.
The aim is to compare outcomes after neoadjuvant chemoradiotherapy with subsequent esophagectomy to definitive chemoradiotherapy with surveillance and salvage esophagectomy as needed in patients with resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalisable guidance for future clinical practice.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Magnus Nilsson, MD, PhD
- Phone Number: +46-707-375186
- Email: magnus.nilsson@ki.se
Study Contact Backup
- Name: Mats Hellström
- Phone Number: +46-8-51773677
- Email: mats.hellstrom@sll.se
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada
- Recruiting
- McGill University Health Centre
-
Contact:
- Mehrnoush Dehgani, PhD
- Email: mehrnoush.dehghani@muhc.mcgill.ca
-
Principal Investigator:
- Lorenzo Ferri, MD, PhD
-
-
-
-
-
Dublin, Ireland, D08 NHY1
- Recruiting
- Cancer Clinical Trials Unit (CCTU) at St. James's Hospital
-
Contact:
- Ingrid Kiernan
- Phone Number: +353 1 4103754
- Email: cancerclinicaltrials@stjames.ie
-
Principal Investigator:
- John Reynolds, Prof
-
Sub-Investigator:
- Grainne O'Kane, Dr
-
Sub-Investigator:
- Moya Cunningham, Dr
-
-
-
-
-
Oslo, Norway
- Recruiting
- Oslo Universitetssykehus
-
Contact:
- Janne Christoffersen, RN
- Email: jannec@ous-hf.no
-
Principal Investigator:
- Ghazwan Al-Haidari, MD, PhD
-
Tromsø, Norway
- Recruiting
- Universitetssykehuset Nord-Norge
-
Contact:
- Eirik Kjus Aahlin, MD, PhD
- Email: eirik.kjus.aahlin@unn.no
-
Contact:
- Kristin Woll, RN
- Email: kristin.woll@unn.no
-
Principal Investigator:
- Eirik Kjus Aahlin, MD, PhD
-
Trondheim, Norway
- Recruiting
- St Olavs Hospital
-
Contact:
- Marte Romundstad, RN
- Email: marte.romunstad@stolav.no
-
Principal Investigator:
- Lars Cato Rekstad, MD, PhD
-
-
-
-
-
Linköping, Sweden
- Recruiting
- Linköpings Universitetssjukhus
-
Contact:
- David Edholm, MD
- Email: david.edholm@regionostergotland.se
-
Contact:
- Anna Lindhoff Larsson, RN
- Email: anna.lindhoff.larsson@regionostergotland.se
-
Lund, Sweden
- Recruiting
- Skånes Universitetssjukhus
-
Contact:
- Monika Meszaros, RN
- Email: monika.meszaros@skane.se
-
Contact:
- Marit Bakos, RN
- Email: marit.bakos@skane.se
-
Principal Investigator:
- Jan Johansson, MD, PhD
-
Stockholm, Sweden
- Recruiting
- Karolinska University Hospital
-
Contact:
- Berit Sunde, RN, PhD
- Email: berit.sunde@ki.se
-
Contact:
- Maria Lampi, RN
- Email: maria.lampi@regionstockholm.se
-
Principal Investigator:
- Magnus Nilsson, MD, PhD
-
Sub-Investigator:
- Gabriella Alexandersson von Döbeln, MD, PhD
-
Umeå, Sweden
- Recruiting
- Norrlands Universitetssjukhus
-
Contact:
- Birgitta Orrvik Olsson, RN
- Email: birgitta.orrvikolsson@regionvasterbotten.se
-
Contact:
- Agneta Karhu, RN
- Email: agneta.karhu@regionvasterbotten.se
-
Principal Investigator:
- Bengt Wallner, MD, PhD
-
Uppsala, Sweden
- Recruiting
- Akademiska Sjukhuset
-
Contact:
- Lena Ekfjord, RN
- Email: lena.ekfjord@akademiska.se
-
Principal Investigator:
- Jakob Hedberg, MD, PhD
-
Örebro, Sweden
- Recruiting
- Örebro Universitetssjukhus
-
Contact:
- Linnea Sundström, RN
- Email: linnea.sundstrom@regionorebrolan.se
-
Principal Investigator:
- Eva Szabo, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histopathologically confirmed SCC of the esophagus in locally advanced stages cT1 N+ or cT2-4a any N, M0, according to current (8th) version of of the AJCC TNM classification.
- Technically resectable disease according to the local multidisciplinary team conference (MDT)/tumor board.
- Performance status ECOG 0-1.
- Adequate organ function.
- Women of childbearing potential (WOCBP*) must have a negative serum or urine pregnancy test.
- Patients of childbearing/reproductive potential should use highly effective method of birth control measures during the study treatment period and for at least five months after the last study treatment.
- Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP/GDPR and national/local regulations.
Exclusion Criteria:
- M1 according to current (8th) version of of the AJCC TNM classification.
- cT4b according to current (8th) version of of the AJCC TNM classification.
- Primary tumor not resectable without laryngectomy.
- Impaired renal, hepatic, cardiac, pulmonary or endocrine status that compromises the eligibility of the patient for multimodality treatment with chemoradiotherapy followed by esophagectomy.
- Subjects not considered likely to tolerate multimodality treatment with chemoradiotherapy followed by esophagectomy.
- Subjects with previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry.
- Prior or concomitant treatment with radiotherapy or chemoradiotherapy with potential overlap of radiotherapy fields.
- Known uncontrollable hypersensitivity to the components of the chemotherapeutic agents used in the trial regimens.
- Inability to fully understand and digest study patient information or to comply with study instructions due to language difficulty or cognitive failure such as dementia or severe psychiatric disorder.
(Criteria slightly shortened)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control arm (A)
Neoadjuvant chemoradiotherapy followed by esophagectomy. Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy. Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy. Esophagectomy: Within 8 weeks of termination of chemoradiotherapy, |
1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
Other Names:
Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
Other Names:
Esophagectomy only in case of residual or recurrent locoregional cancer.
|
Experimental: Experimental arm (B)
Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer. Radiotherapy: Two alternative schemes:
Chemotherapy: Three alternative regimens: 1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy. 2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5. 2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5. |
Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
Other Names:
Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
Other Names:
Esophagectomy only in case of residual or recurrent locoregional cancer.
Two alternative schemes:
Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
Other Names:
FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Health-related quality of life (HRQOL)
Time Frame: 1 year after randomisation
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, version 3.0 (EORTC QLQ-C30).
The two items assessing global health and overall quality of life are responded to in seven categories ranging from 1 (very poor) to 7 (excellent).
|
1 year after randomisation
|
Overall survival
Time Frame: 3 years after randomisation
|
When 398 events have occurred
|
3 years after randomisation
|
Eating restrictions
Time Frame: 1 year after randomisation
|
EORTC QLQ-OG25 instrument.
This instrument consists of 25 items covering upper gastric symptoms or problems in four categories ranging from 1 (Not at all) to 4 (Very much).
|
1 year after randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health related quality of life of Cancer patients
Time Frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
EORTC HRQOL Questionnaire QLQ-C30 version 3.0, 28 items ranging from 1 (no problems at all) to 4 (very much) and two items assessing global health and overall quality of life are responded to in seven categories ranging from 1 (very poor) to 7 (excellent).
|
At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
Health related quality of life, oesophageal specific.
Time Frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
EORTC HRQOL gastresophageal-specific questionnaire EORTC QLQ-OG25.
25 items assessing symptoms or problems are responded to in four categories ranging from 1 (no problems) to 4 (very much).
|
At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
Health related quality of life, general health
Time Frame: At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
The EuroQoL Group's EQ-5D-5L questionnaire consisting of five dimensions ranging from No problems to Extreme problems or Unable to care.
|
At randomisation but before start of treatment and thereafter 6, 12, 24, 36 and 60 months after randomisation
|
Event-free survival
Time Frame: 5 years after randomisation
|
Time to relapse, initiation of any anti-tumor therapy beyond the study treatments (salvage surgery is considered a study treatment in the dCRT arm), or death, whichever comes first.
|
5 years after randomisation
|
Loco-regional and distant relapse rates
Time Frame: 5 years after randomisation
|
Including the relation of relapse location to the radiation field
|
5 years after randomisation
|
Histopathological response according to Mandard in operated patients
Time Frame: 5 years after randomisation
|
ypTNM including total and metastatic lymph node count, tumor free resection margins, R0
|
5 years after randomisation
|
Health economy
Time Frame: At baseline and 6, 12, 24, 36 and 60 months after randomisation
|
Assessed including patient-level medical resource use and societal costs due to sick-leave and other non-medical costs.
Quality-adjusted life years (QALYs) will be calculated using EQ-5D
|
At baseline and 6, 12, 24, 36 and 60 months after randomisation
|
Surgical complications
Time Frame: After surgery in operated patients, up to 5 years after randomisation
|
According to the Esophagectomy Complications Consensus Group (ECCG) and classified according to Clavien-Dindo
|
After surgery in operated patients, up to 5 years after randomisation
|
Treatment-related adverse events and toxicity
Time Frame: Up to 5 years after randomisation
|
NCI-CTCAE Criteria version 5.0
|
Up to 5 years after randomisation
|
Nutritional outcomes - weight
Time Frame: Up to 5 years after randomisation
|
Weight development.
Weight (in kg) will be measured at all visits.
|
Up to 5 years after randomisation
|
Nutritional outcomes - dysphagia
Time Frame: Up to 5 years after randomisation
|
Dysphagia will be evaluated at all visits according to the CTC adverse event scale, grading from 0 (no problems) to 4 (worst problems).
|
Up to 5 years after randomisation
|
Gender stratified analyses of all endpoints
Time Frame: Up to 5 years after randomisation
|
Up to 5 years after randomisation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Magnus Nilsson, MD, PhD, Karolinska University Hospital
- Study Chair: Florian Lordick, MD, PhD, Leipzig University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Micronutrients
- Vitamins
- Calcium-Regulating Hormones and Agents
- Antidotes
- Vitamin B Complex
- Carboplatin
- Paclitaxel
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Calcium
- Levoleucovorin
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- NEEDS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Fujian Medical University Union HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IVChina
-
The First Affiliated Hospital of Henan University...Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaboratorsActive, not recruitingStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage IIIChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell CarcinomaChina
Clinical Trials on Neoadjuvant radiotherapy (arm A)
-
University Hospital, Basel, SwitzerlandETOP IBCSG Partners Foundation; Austrian Breast Cancer Study GroupRecruitingNode-positive Breast CancerGreece, Switzerland, Hungary, Austria, Germany, Italy, Lithuania, Argentina, Croatia
-
University Hospital FreiburgGerman Federal Ministry of Education and ResearchRecruiting
-
Lawson Health Research InstituteRecruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Azienda Ospedaliero-Universitaria CareggiRecruitingEarly Breast CancerItaly
-
Changhai HospitalRecruiting
-
Hubei Cancer HospitalRecruitingBreast Cancer | Implant Breast Reconstruction | Neoadjuvant RadiotherapyChina
-
Fudan UniversityRecruiting
-
UMC UtrechtAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Alexander...Recruiting
-
Region SkaneCompleted
-
Ottawa Hospital Research InstituteUnknown